SCYX SCYNEXIS, Inc.
4.780USD-1.24%Mkt Cap: 47.56M $P/E: —1d ago
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the…
Industry Peers
Drug Manufacturers - Specialty & Generic$66.23BUSDP/E 25.7
$58.68BUSD
$45.70BUSDP/E 65.3
GALD
Galderma Group AG$43.27BUSDP/E 56.1
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG$34.93BUSDP/E 60.5
HLN
Haleon plc$32.73BUSDP/E 19.0
$29.57BUSDP/E 11.8
$28.56BUSDP/E 12.2
$23.38BUSDP/E 19.5
$20.09BUSD
$14.43BUSDP/E 112.9
$14.58BUSDP/E 21.0
$12.99BUSDP/E 23.5
$11.17BUSD
$10.22BUSDP/E 27.9
$8.66BUSDP/E 19.3
$6.95BUSDP/E 109.1
$6.89BUSD
$6.84BUSDP/E 40.1
| Headline | Source | Time |
|---|---|---|
Older | ||
Scynexis stock surges on $214M BARDA contract for SCY-247 Investing.com -- Scynexis Inc (NASDAQ:SCYX) shares jumped 10% in premarket trading Monday after the company announced it secured a contract from the Biomedical Advanced Research and Development Authority worth up to $214 million. | ||
 Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract Scynexis (NASDAQ:SCYX) shares rose 13. 9% in pre-market trading after the company announced a contract with the U. | ||